JP2018502828A5 - - Google Patents

Download PDF

Info

Publication number
JP2018502828A5
JP2018502828A5 JP2017527368A JP2017527368A JP2018502828A5 JP 2018502828 A5 JP2018502828 A5 JP 2018502828A5 JP 2017527368 A JP2017527368 A JP 2017527368A JP 2017527368 A JP2017527368 A JP 2017527368A JP 2018502828 A5 JP2018502828 A5 JP 2018502828A5
Authority
JP
Japan
Prior art keywords
mutations
lung cancer
aforementioned
immune checkpoint
synonymous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017527368A
Other languages
English (en)
Japanese (ja)
Other versions
JP7173733B2 (ja
JP2018502828A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/062208 external-priority patent/WO2016081947A2/en
Publication of JP2018502828A publication Critical patent/JP2018502828A/ja
Priority to JP2022129458A priority Critical patent/JP7550193B2/ja
Publication of JP2018502828A5 publication Critical patent/JP2018502828A5/ja
Application granted granted Critical
Publication of JP7173733B2 publication Critical patent/JP7173733B2/ja
Priority to JP2024107117A priority patent/JP2024125234A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017527368A 2014-11-21 2015-11-23 Ｐｄ－１遮断による免疫療法の癌奏効の決定因子 Active JP7173733B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022129458A JP7550193B2 (ja) 2014-11-21 2022-08-16 Ｐｄ－１遮断による免疫療法の癌奏効の決定因子
JP2024107117A JP2024125234A (ja) 2014-11-21 2024-07-03 Ｐｄ－１遮断による免疫療法の癌奏効の決定因子

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462083088P 2014-11-21 2014-11-21
US62/083,088 2014-11-21
US201562132381P 2015-03-12 2015-03-12
US62/132,381 2015-03-12
PCT/US2015/062208 WO2016081947A2 (en) 2014-11-21 2015-11-23 Determinants of cancer response to immunotherapy by pd-1 blockade

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2020135853A Division JP2020196732A (ja) 2014-11-21 2020-08-11 Ｐｄ−１遮断による免疫療法の癌奏効の決定因子
JP2022129458A Division JP7550193B2 (ja) 2014-11-21 2022-08-16 Ｐｄ－１遮断による免疫療法の癌奏効の決定因子

Publications (3)

Publication Number Publication Date
JP2018502828A JP2018502828A (ja) 2018-02-01
JP2018502828A5 true JP2018502828A5 (https=) 2022-09-01
JP7173733B2 JP7173733B2 (ja) 2022-11-16

Family

ID=56014697

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017527368A Active JP7173733B2 (ja) 2014-11-21 2015-11-23 Ｐｄ－１遮断による免疫療法の癌奏効の決定因子
JP2020135853A Withdrawn JP2020196732A (ja) 2014-11-21 2020-08-11 Ｐｄ−１遮断による免疫療法の癌奏効の決定因子
JP2022129458A Active JP7550193B2 (ja) 2014-11-21 2022-08-16 Ｐｄ－１遮断による免疫療法の癌奏効の決定因子
JP2024107117A Pending JP2024125234A (ja) 2014-11-21 2024-07-03 Ｐｄ－１遮断による免疫療法の癌奏効の決定因子

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020135853A Withdrawn JP2020196732A (ja) 2014-11-21 2020-08-11 Ｐｄ−１遮断による免疫療法の癌奏効の決定因子
JP2022129458A Active JP7550193B2 (ja) 2014-11-21 2022-08-16 Ｐｄ－１遮断による免疫療法の癌奏効の決定因子
JP2024107117A Pending JP2024125234A (ja) 2014-11-21 2024-07-03 Ｐｄ－１遮断による免疫療法の癌奏効の決定因子

Country Status (8)

Country Link
US (3) US20180291074A1 (https=)
EP (2) EP4393546A3 (https=)
JP (4) JP7173733B2 (https=)
CN (2) CN107206064B (https=)
AU (3) AU2015349644B2 (https=)
HK (1) HK1244440A1 (https=)
MA (1) MA40737A (https=)
WO (1) WO2016081947A2 (https=)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
SG10201804945WA (en) 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
EP3212670B1 (en) 2014-10-29 2020-12-23 Five Prime Therapeutics, Inc. Combination therapy for cancer
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
ES2970865T3 (es) 2015-12-16 2024-05-31 Gritstone Bio Inc Identificación, fabricación y uso de neoantígenos
IL260030B2 (en) 2016-01-08 2025-12-01 Nykode Therapeutics ASA Therapeutic anticancer neoepitope vaccine
CA3015913A1 (en) 2016-02-29 2017-09-08 Foundation Medicine, Inc. Methods of treating cancer
JP6821693B2 (ja) * 2016-02-29 2021-01-27 ジェネンテック， インコーポレイテッド がんのための治療方法及び診断方法
WO2017151727A1 (en) * 2016-03-01 2017-09-08 North Carolina State University Enhanced cancer immunotherapy by microneedle patch-assisted delivery
JP7147168B2 (ja) * 2016-03-02 2022-10-05 東レ株式会社 免疫誘導剤
EP3464360B1 (en) 2016-05-27 2025-11-12 Agenus Inc. Anti-tim-3 antibodies and methods of use thereof
WO2018003995A1 (ja) * 2016-07-01 2018-01-04 国立大学法人東北大学 免疫チェックポイント阻害薬使用における免疫関連副作用の予測方法
EP3500966B1 (en) * 2016-08-25 2021-04-21 Nantomics, LLC Immunotherapy markers and uses therefor
CA3038712A1 (en) 2016-10-06 2018-04-12 Genentech, Inc. Therapeutic and diagnostic methods for cancer
JP7295015B2 (ja) * 2016-10-07 2023-06-20 オムニセック インコーポレイテッド 個別化治療を決定するための方法
WO2018132753A1 (en) * 2017-01-13 2018-07-19 Nantbio, Inc. Validation of neoepitope-based treatment
WO2018136664A1 (en) 2017-01-18 2018-07-26 Ichan School Of Medicine At Mount Sinai Neoantigens and uses thereof for treating cancer
BR112019015797A2 (pt) 2017-02-01 2020-03-17 Modernatx, Inc. Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação
CN110461342A (zh) * 2017-02-06 2019-11-15 诺华股份有限公司 预测对免疫疗法的反应的方法
EP3494235A1 (en) * 2017-02-17 2019-06-12 Stichting VUmc Swarm intelligence-enhanced diagnosis and therapy selection for cancer using tumor- educated platelets
US10859566B2 (en) * 2017-03-20 2020-12-08 Genocea Biosciences, Inc. Treatment methods
EP3601355A1 (en) * 2017-03-31 2020-02-05 Bristol-Myers Squibb Company Methods of treating tumor
GB201710815D0 (en) * 2017-07-05 2017-08-16 Francis Crick Inst Ltd Method
JP7760242B2 (ja) 2017-07-21 2025-10-27 ジェネンテック， インコーポレイテッド がんの治療法及び診断法
JP7274454B2 (ja) * 2017-07-28 2023-05-16 ブリストル－マイヤーズ スクイブ カンパニー チェックポイント阻害薬のための予測末梢血バイオマーカー
EP3681535A1 (en) * 2017-09-13 2020-07-22 Five Prime Therapeutics, Inc. Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
WO2019055860A1 (en) * 2017-09-15 2019-03-21 The Texas A&M University System METHODS FOR IMPROVING IMMUNOTHERAPY IN THE TREATMENT OF CANCER
CN117987553A (zh) 2017-09-25 2024-05-07 纪念斯隆凯特琳癌症中心 肿瘤突变负荷和检查点免疫疗法
CA3076918A1 (en) * 2017-10-02 2019-04-11 Curematch, Inc. Method of prediction of tumor-derived neo-peptide antigenicity and/or immunogenicity using mutational signature patterns
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
WO2019075251A2 (en) * 2017-10-12 2019-04-18 Nantomics, Llc CANCER SCORE FOR EVALUATION AND PREDICTION OF RESPONSE FROM BIOLOGICAL FLUIDS
CN111247169A (zh) * 2017-10-15 2020-06-05 百时美施贵宝公司 治疗肿瘤的方法
WO2019090156A1 (en) 2017-11-03 2019-05-09 Guardant Health, Inc. Normalizing tumor mutation burden
EP3710600B1 (en) * 2017-11-17 2025-03-12 GMDx Co Pty Ltd Systems and methods for predicting the efficacy of cancer therapy
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
WO2019109086A1 (en) 2017-12-01 2019-06-06 Illumina, Inc. Methods and systems for determining somatic mutation clonality
US20210054465A1 (en) * 2018-05-03 2021-02-25 Roche Sequencing Solutions, Inc. Surrogate marker and method for tumor mutation burden measurement
MX2020011684A (es) * 2018-05-04 2020-12-10 Merck Patent Gmbh Inhibicion combinada de pd-1/pd-l1, tgfbeta y dna-pk para el tratamiento del cancer.
WO2020023420A2 (en) 2018-07-23 2020-01-30 Guardant Health, Inc. Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage
WO2020021119A1 (en) 2018-07-27 2020-01-30 F. Hoffmann-La Roche Ag Method of monitoring effectiveness of immunotherapy of cancer patients
WO2020045479A1 (ja) 2018-08-29 2020-03-05 公益財団法人東京都医学総合研究所 ＨＧＦ－ｒｅｇｕｌａｔｅｄ ｔｙｒｏｓｉｎｅ ｋｉｎａｓｅ ｓｕｂｓｔｒａｔｅ（ＨＧＳ）を標的とした抗腫瘍剤
CN121354685A (zh) 2018-08-31 2026-01-16 夸登特健康公司 无细胞dna中的微卫星不稳定性检测
JP7623281B2 (ja) 2018-11-15 2025-01-28 パーソナル ゲノム ダイアグノスティクス インコーポレイテッド 免疫療法で治療されたがん患者の応答の予測を改善する方法
US20200190598A1 (en) * 2018-12-12 2020-06-18 Medimmune, Llc Blood-based tumor mutation burden predicts overall survival in nsclc
EP3982954A4 (en) 2019-06-14 2024-01-03 The Trustees of Columbia University in the City of New York NT5C2 INHIBITORS FOR THE TREATMENT OF CHEMOTHERAPY-RESISTANT ACUTE LYMPHOBLASTIC LEUKEMIA
AU2020376937A1 (en) * 2019-11-01 2022-06-09 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. HLA class I sequence divergence and cancer therapy
GB202003669D0 (en) * 2020-03-13 2020-04-29 Univ Oxford Innovation Ltd Method for identifying neo-antigens
EP4143345A1 (en) * 2020-04-28 2023-03-08 Genentech, Inc. Methods and compositions for non-small cell lung cancer immunotherapy
AU2021285711A1 (en) * 2020-06-01 2023-01-05 Gmdx Co Pty Ltd Methods of predicting cancer progression
CN112309502B (zh) * 2020-10-14 2024-09-20 深圳市新合生物医疗科技有限公司 一种计算肿瘤新抗原负荷的方法及系统
WO2022099004A1 (en) * 2020-11-06 2022-05-12 The General Hospital Corporation Methods for characterizing biological samples
US20240238340A1 (en) * 2021-05-03 2024-07-18 Rutgers, The State University Of New Jersey Immunotherapy for inflammatory bowel disease and/or cancer
CN113030475B (zh) * 2021-05-25 2021-08-10 泛肽生物科技(浙江)有限公司 一种基于细胞线粒体质量评估的t细胞pd-1检测方法
CN113355424B (zh) * 2021-07-14 2022-03-25 江苏先声医学诊断有限公司 Pcdh11x突变在预测非小细胞肺癌患者对免疫检查点抑制剂疗法敏感性中的应用
WO2024216165A1 (en) 2023-04-12 2024-10-17 Icahn School Of Medicine At Mount Sinai Computational methods for selecting personalized neoantigen vaccines

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033497A1 (en) 2002-08-13 2004-02-19 Alarcon-Riquelme Marta E. Polymorphisms of PD-1
TWI477602B (zh) 2006-02-09 2015-03-21 Educational Foundation Jichi Medical Univ Novel viral vector
AU2010319322A1 (en) * 2009-11-13 2012-05-31 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
EA201690310A1 (ru) * 2010-04-13 2016-12-30 Селлдекс Терапьютикс Инк. Антитела, связывающие cd27 человека, и их применение
EP2569633B1 (en) * 2010-05-14 2016-02-10 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
WO2013130748A1 (en) * 2012-02-29 2013-09-06 The Regents Of The University Of Michigan Prostate cancer markers and uses thereof
RU2737765C2 (ru) 2012-05-04 2020-12-02 Пфайзер Инк. Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
LT2901341T (lt) 2012-09-28 2019-09-25 The University Of Connecticut Protekcinių vėžio epitopų identifikavimas, skirtas vėžio gydymui
EP3090066A4 (en) * 2014-01-02 2017-08-30 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy
KR20230030022A (ko) * 2014-11-13 2023-03-03 더 존스 홉킨스 유니버시티 관문 차단 및 미소부수체 불안정성
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
CN117987553A (zh) * 2017-09-25 2024-05-07 纪念斯隆凯特琳癌症中心 肿瘤突变负荷和检查点免疫疗法

Similar Documents

Publication Publication Date Title
JP2018502828A5 (https=)
Succony et al. Adenocarcinoma spectrum lesions of the lung: Detection, pathology and treatment strategies
Lee et al. Identification of human complement factor B as a novel biomarker candidate for pancreatic ductal adenocarcinoma
Liu et al. Heterogeneity of PD-L1 expression among the different histological components and metastatic lymph nodes in patients with resected lung adenosquamous carcinoma
Shah et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer
Shay et al. Bacteriome and mycobiome and bacteriome-mycobiome interactions in head and neck squamous cell carcinoma
US20200109455A1 (en) Systems and methods for predicting clinical responses to immunotherapies
WO2021175746A1 (en) Prediction of radiotherapy response for prostate cancer subject based on immune defense response genes
WO2022069201A1 (en) Prediction of an outcome of a bladder or kidney cancer subject
Li et al. Lung cancer-associated T cell repertoire as potential biomarker for early detection of stage I lung cancer
Bogusz et al. Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets
Abazari et al. Estimation of survival rates in patients with lung cancer in west Azerbaijan, the northwest of Iran
Li et al. Prognostic model for risk stratification of de novo metastatic nasopharyngeal carcinoma patients treated with chemotherapy followed by locoregional radiotherapy
CN105574365A (zh) 高通量测序突变检测结果的统计学验证方法
CN111321225A (zh) 一种基于lncRNA评分体系在预测肿瘤免疫治疗效果中的应用
Aoki et al. Greater extent of blood‐tumor TCR repertoire overlap is associated with favorable clinical responses to PD‐1 blockade
Li et al. Features and efficacy of triple-targeted therapy for patients with EGFR-mutant non-small-cell lung cancer with acquired BRAF alterations who are resistant to epidermal growth factor receptor tyrosine kinase inhibitors
Campo-Le-Brun et al. Real-world efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient biliary tract cancer: An AGEO study
Nawaz et al. Association of the rs10757274 SNP with coronary artery disease in a small group of a Pakistani population
Devarakonda et al. Next-generation sequencing of lung cancers: lessons learned and future directions
Kim et al. Assessment of Anti-tumor Efficacy of Osimertinib in Non–Small Cell Lung Cancer Patients by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma, or Pleural Effusion
Inokuchi et al. Cadherin 5 is a significant risk factor for hematogenous recurrence and a prognostic factor in locally advanced gastric cancer
Sklodowski et al. 59 Integrating deep proteomics profiling with survival analysis to identify novel biomarkers of response to PD-1 blockade in NSCLC patients
Thursby et al. Epigenetic Instability Based Metrics in Cell-Free DNA for Early Cancer Detection
Chen et al. 169p anlotinib plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: A prospective, single-arm, single-center, phase ii clinical study